173 related articles for article (PubMed ID: 32604836)
1. Tracing Nutrient Flux Following Monocarboxylate Transporter-1 Inhibition with AZD3965.
Braga M; Kaliszczak M; Carroll L; Schug ZT; Heinzmann K; Baxan N; Benito A; Valbuena GN; Stribbling S; Beckley A; Mackay G; Mauri F; Latigo J; Barnes C; Keun H; Gottlieb E; Aboagye EO
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32604836
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.
Curtis NJ; Mooney L; Hopcroft L; Michopoulos F; Whalley N; Zhong H; Murray C; Logie A; Revill M; Byth KF; Benjamin AD; Firth MA; Green S; Smith PD; Critchlow SE
Oncotarget; 2017 Sep; 8(41):69219-69236. PubMed ID: 29050199
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
4. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of metabolism-related biomarkers in non-Hodgkin lymphoma - MCT1 as potential target in diffuse large B cell lymphoma.
Afonso J; Pinto T; Simões-Sousa S; Schmitt F; Longatto-Filho A; Pinheiro C; Marques H; Baltazar F
Cell Oncol (Dordr); 2019 Jun; 42(3):303-318. PubMed ID: 30790227
[TBL] [Abstract][Full Text] [Related]
6. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
7. In Vitro and In Vivo Characterization of MCT1 Inhibitor AZD3965 Confirms Preclinical Safety Compatible with Breast Cancer Treatment.
Benyahia Z; Blackman MCNM; Hamelin L; Zampieri LX; Capeloa T; Bedin ML; Vazeille T; Schakman O; Sonveaux P
Cancers (Basel); 2021 Feb; 13(3):. PubMed ID: 33540599
[TBL] [Abstract][Full Text] [Related]
8. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
Guan X; Morris ME
AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599
[TBL] [Abstract][Full Text] [Related]
9. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
[TBL] [Abstract][Full Text] [Related]
10. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration.
Beloueche-Babari M; Casals Galobart T; Delgado-Goni T; Wantuch S; Parkes HG; Tandy D; Harker JA; Leach MO
Br J Cancer; 2020 Mar; 122(6):895-903. PubMed ID: 31937921
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
[TBL] [Abstract][Full Text] [Related]
12. Radiosynthesis and validation of (±)-[18F]-3-fluoro-2-hydroxypropionate ([18F]-FLac) as a PET tracer of lactate to monitor MCT1-dependent lactate uptake in tumors.
Van Hée VF; Labar D; Dehon G; Grasso D; Grégoire V; Muccioli GG; Frédérick R; Sonveaux P
Oncotarget; 2017 Apr; 8(15):24415-24428. PubMed ID: 28107190
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.
Bola BM; Chadwick AL; Michopoulos F; Blount KG; Telfer BA; Williams KJ; Smith PD; Critchlow SE; Stratford IJ
Mol Cancer Ther; 2014 Dec; 13(12):2805-16. PubMed ID: 25281618
[TBL] [Abstract][Full Text] [Related]
14. Effects of Lactate Transport Inhibition by AZD3965 in Muscle-Invasive Urothelial Bladder Cancer.
Silva A; Félix A; Cerqueira M; Gonçalves CS; Sampaio-Marques B; Longatto-Filho A; Baltazar F; Afonso J
Pharmaceutics; 2023 Nov; 15(12):. PubMed ID: 38140029
[TBL] [Abstract][Full Text] [Related]
15. Effects of a monocarboxylate transport 1 inhibitor, AZD3965, on retinal and visual function in the rat.
Allen AE; Martin EA; Greenwood K; Grant C; Vince P; Lucas RJ; Redfern WS
Br J Pharmacol; 2020 Oct; 177(20):4734-4749. PubMed ID: 32833237
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma.
Noble RA; Thomas H; Zhao Y; Herendi L; Howarth R; Dragoni I; Keun HC; Vellano CP; Marszalek JR; Wedge SR
Br J Cancer; 2022 Sep; 127(5):937-947. PubMed ID: 35618788
[TBL] [Abstract][Full Text] [Related]
17. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors.
Boidot R; Végran F; Meulle A; Le Breton A; Dessy C; Sonveaux P; Lizard-Nacol S; Feron O
Cancer Res; 2012 Feb; 72(4):939-48. PubMed ID: 22184616
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin lymphoma: A complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment.
Mikkilineni L; Whitaker-Menezes D; Domingo-Vidal M; Sprandio J; Avena P; Cotzia P; Dulau-Florea A; Gong J; Uppal G; Zhan T; Leiby B; Lin Z; Pro B; Sotgia F; Lisanti MP; Martinez-Outschoorn U
Semin Oncol; 2017 Jun; 44(3):218-225. PubMed ID: 29248133
[TBL] [Abstract][Full Text] [Related]
19. Enhanced glucose metabolism mediated by CD147 is associated with
Zhang Y; Liu J; Sun Y; Yu X; Wang J; Dai D; Zhu Y; Song X; Zhu L; Li X; Xu W
Thorac Cancer; 2020 May; 11(5):1245-1257. PubMed ID: 32162491
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.
Halford S; Veal GJ; Wedge SR; Payne GS; Bacon CM; Sloan P; Dragoni I; Heinzmann K; Potter S; Salisbury BM; Chénard-Poirier M; Greystoke A; Howell EC; Innes WA; Morris K; Plummer C; Rata M; Petrides G; Keun HC; Banerji U; Plummer R
Clin Cancer Res; 2023 Apr; 29(8):1429-1439. PubMed ID: 36652553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
